Healthy men to test cheaper version of blockbuster allergy drug
NCT ID NCT07334496
First seen Jan 12, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study checks if a new drug, GLR1044, works the same as the approved drug Dupilumab (Dupixent®) in 198 healthy Chinese men. Each person gets one shot and is followed for 57 days to measure drug levels and safety. The goal is to see if GLR1044 can be a more affordable option for treating conditions like asthma and eczema.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOSIMILARITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.